Laekna, Inc. (SEHK: 2105)
Health Care · Biotechnology · CN
HK$7.37
-15.77% today · -49.0% 1Y
Laekna, Inc. (SEHK: 2105) operates in the Biotechnology industry within the Health Care sector. The company is valued at $400.21M and employs 83 people.
Over the last twelve months the share price has lost 49.0%, trading between 5.37 and 19.36.
Tweenvest scores Laekna, Inc. across four factors: quality 41/100, value 68/100. Its strongest factor is value.
2105 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $400.21M
- Revenue (TTM)
- $37.83M
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- -1.19
- 52-week high
- HK$19.36
- 52-week low
- HK$5.37
- Avg volume (3M)
- —
- Shares outstanding
- 426.15M
- Employees
- 83
- Next earnings
- —
About Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
- ISIN
- KYG5340S1093
- Founded
- 2016
- Listed since
- Jun 28, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Guangdong VTR Bio-Tech Co., Ltd.SZSE: 300381 | $406.47M | CN¥5.67 | -0.35% |
| GI Innovation, Inc.KOSDAQ: A358570 | $405.99M | ₩8,460.00 | -4.08% |
| AP Biosciences, Inc.TPEX: 6945 | $405.68M | NT$133.00 | -2.21% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $400.65M | $3.74 | -3.86% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $397.35M | $3.87 | -1.78% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $393.24M | $7.26 | -2.81% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $12.61 | -8.22% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $30.46 | -2.31% |
Figures last refreshed Oct 11, 2026.